November 17, 2026

To whom it may concern

Company Name: Innovacell Inc.
Representative: Representative Director and Co-CEO Colin Novick
Representative: Representative Director and Co-CEO Jason Sieger
(Securities Code: 504A, Growth Market of the Tokyo Stock Exchange)
Point of Contact: Director and CFO Yasushi Hosono
(https://innovacell.com/contact/?lang=en)

Notice Regarding the Release of English Presentation Video of Q3 FY2026 Progress Update

We hereby announce that we have released a webinar recording outlining our progress for the third quarter of the fiscal year ending December 2026. The English presentation material can be viewed at the URLs on our corporate website as well as Logmi Finance YouTube below. We hope this video will serve as a useful reference for gaining a deeper understanding of the progress of Innovacell Group's business operations.

1. Release date: November 17, 2026
2. Video URLs: (Corporate website) https://innovacell.com/third-quarter-fy2026-progress-update-video/?lang=en
   (YouTube) https://www.youtube.com/watch?v=1IzR0UNkNMo
   (Logmi Finance YouTube) https://youtu.be/Uuy6QsXXgl0
3. Presentation Material URL: https://ssl4.eir-parts.net/doc/504A/tdnet/2914266/00.pdf

■ About Innovacell:

Innovacell Inc. was established in Japan in 2021 as the parent company of a regenerative medicine company spun off from the Medical University of Innsbruck in Austria, and was listed on the Tokyo Stock Exchange Growth Market in February 2026 (Securities Code: 504A).

Our Group aims to improve people's health and quality of life through the commercialization of cell therapy and regenerative medicine, and we are currently engaged in the research, development, and commercialization of regenerative medicine products for the treatment of incontinence (urge fecal incontinence, passive fecal incontinence, and stress urinary incontinence). To date, our Group has completed multiple clinical trials in Europe (including late-stage Phase II trials) for two pipeline programs: ICEF15 (target indication: urge fecal incontinence) and ICES13 (target indication: stress urinary incontinence). For more details, please visit our website or our YouTube channel.

End